EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
…, G Valesini, R Van Vollenhoven, KL Winthrop… - Annals of the …, 2010 - ard.bmj.com
Treatment of rheumatoid arthritis (RA) may differ among rheumatologists and currently, clear
and consensual international recommendations on RA treatment are not available. In this …
and consensual international recommendations on RA treatment are not available. In this …
[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …
…, LW Moreland, J O'Dell, KL Winthrop… - Arthritis care & …, 2012 - Wiley Online Library
… Winthrop has received consultant fees, speaking fees, and/or honoraria (less than $10,000
each) from Abbott, Amgen, Pfizer, Cellestis, and Wyeth. Dr. Chatham has served as a paid …
each) from Abbott, Amgen, Pfizer, Cellestis, and Wyeth. Dr. Chatham has served as a paid …
[HTML][HTML] European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
…, G Valesini, J Vencovsky, KL Winthrop… - Annals of the …, 2012 - ard.bmj.com
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual
treatment guidance focused on the musculoskeletal manifestations of PsA would be …
treatment guidance focused on the musculoskeletal manifestations of PsA would be …
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
…, J Van Ingen, D Wagner, KL Winthrop - Clinical Infectious …, 2020 - academic.oup.com
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of
which can produce disease in humans of all ages and can affect both pulmonary and …
which can produce disease in humans of all ages and can affect both pulmonary and …
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study
…, M Villar, R Walkiewicz, KL Winthrop… - European …, 2013 - Eur Respiratory Soc
A significant knowledge gap exists concerning the geographical distribution of nontuberculous
mycobacteria (NTM) isolation worldwide. To provide a snapshot of NTM species …
mycobacteria (NTM) isolation worldwide. To provide a snapshot of NTM species …
The emerging safety profile of JAK inhibitors in rheumatic disease
KL Winthrop - Nature Reviews Rheumatology, 2017 - nature.com
Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment
of rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …
of rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the …
JL Nam, KL Winthrop, RF van Vollenhoven… - Annals of the …, 2010 - ard.bmj.com
Objectives To review the evidence for the efficacy and safety of biological agents in patients
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
with rheumatoid arthritis (RA) to provide data to develop treatment recommendations by the …
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in …
…, AR Smyth, J Van Ingen, RJ Wallace, KL Winthrop… - Thorax, 2016 - thorax.bmj.com
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause
chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung …
chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
…, T Takeuchi, P Verschueren, KL Winthrop… - Annals of the …, 2023 - ard.bmj.com
… EMEUNET, the EULAR network of young rheumatologists, was also represented (KL and
FR). Most people attended the face-to-face meeting in Zurich in April 2022; some of the …
FR). Most people attended the face-to-face meeting in Zurich in April 2022; some of the …
Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology
…, A Saulson, E McNelly, KL Winthrop - Clinical Infectious …, 2009 - academic.oup.com
… Kevin L Winthrop Kevin L Winthrop … Maureen Cassidy, Katrina Hedberg, Ashlen Saulson,
Erin McNelly, Kevin L Winthrop, Nontuberculous Mycobacterial Disease Prevalence and Risk …
Erin McNelly, Kevin L Winthrop, Nontuberculous Mycobacterial Disease Prevalence and Risk …